ELTP — Elite Pharmaceuticals Balance Sheet
0.000.00%
- $658.64m
 - $641.67m
 - $84.04m
 
- 94
 - 31
 - 43
 - 58
 
Annual balance sheet for Elite Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st  | 2022 March 31st  | 2023 March 31st  | 2024 March 31st  | 2025 March 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Short Term Investments | 3.19 | 8.54 | 7.83 | 7.11 | 11.3 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.5 | 3.06 | 3.09 | 19.5 | 29.2 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 12.2 | 18.9 | 21.5 | 40 | 57.7 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.86 | 6.98 | 10.4 | 14.6 | 14.1 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 26.2 | 35.1 | 40.9 | 83.7 | 96.4 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.81 | 6.69 | 7.83 | 13 | 11.8 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10 | 9.93 | 11.9 | 26.1 | 42.9 | 
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 16.2 | 25.2 | 29 | 57.6 | 53.5 | 
| Total Liabilities & Shareholders' Equity | 26.2 | 35.1 | 40.9 | 83.7 | 96.4 | 
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |